ziconotide-snail venom used for Neuropathic pain

[Guest guest]

http://www.mtdesk.com/z.shtml

ziconotide (previously designated SNX-111)

An investigational pain therapeutic, previously referred to as SNX-111, in

phase III trials for the treatment of neuropathic

pain in patients who are unresponsive to traditional pain-management

therapies, including opioid therapy. Product is also

in phase II trials for the treatment of postsurgical pain. NDA for use in

the management of chronic neuropathic and

malignant pain is planned for the end of 1999. Mfg/Source: Elan

Corporation. Additional source: PR Newswire -

12/14/98, 04/14/99.